Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3SLC6A2
The experimentally established mechanism targets of Racephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.71 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.71 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | RGS12 | O14924 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racephedrine SCHEMBL2081241 | 1.00 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2081239 | 1.00 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL3079358 | 0.98 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL3079361 | 0.98 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL1785211 | 0.98 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2323883 | 0.92 | ADRA2C (0.73) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL8728628 | 0.90 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8728630 | 0.90 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8733657 | 0.85 | ALDH1A1 (0.67) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL8733656 | 0.85 | ALDH1A1 (0.67) | ADRA2CADRA1ACHRM2RGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5760237-A | Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-06-02 | — | — | US | claimed |
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| US-11498917-B2 | Process for the preparation of lifitegrast | OLON S.P.A. (IT) | 2022-11-15 | — | — | US | disclosed |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON S.P.A. (IT) | 2021-08-12 | — | — | US | disclosed |
| EP-3807268-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON S.p.A. (IT) | 2021-04-21 | — | — | EP | disclosed |
| US-6034247-A | REACTIG A UNSATURSATED CARBOXYLATED AMINE WITH A BASE; CYCLIZATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-03-07 | — | — | US | disclosed |
| WO-1998046577-A1 | NOVEL OXAZOLIDINONES AND METHODS FOR THE SYNTHESIS AND USE OF SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5760237-A | Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5760237-A | Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498917-B2 | Process for the preparation of lifitegrast | LIFR, FLT3, F12 | ADRA2C 944/4885ADRA1A 2711/4885SLC6A2 4220/4885 |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | LIFR, FLT3, F12 | ADRA2C 944/4885ADRA1A 2711/4885SLC6A2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.